AMNEAL PHARMACEUTICALS ($AMRX) posted quarterly earnings results for Q4 2025 on Friday, February 27th. The company reported earnings of $0.21 per share, beating estimates of $0.19 by $0.02. The company also reported revenue of $814,320,000, missing estimates of $824,053,410 by $-9,733,410.
You can see Quiver Quantitative's $AMRX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AMNEAL PHARMACEUTICALS Insider Trading Activity
AMNEAL PHARMACEUTICALS insiders have traded $AMRX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $AMRX stock by insiders over the last 6 months:
- NIKITA SHAH (Executive Vice President) sold 131,856 shares for an estimated $1,571,723
- TED C NARK sold 50,000 shares for an estimated $586,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AMNEAL PHARMACEUTICALS Hedge Fund Activity
We have seen 146 institutional investors add shares of AMNEAL PHARMACEUTICALS stock to their portfolio, and 129 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 1,777,048 shares (-42.1%) from their portfolio in Q4 2025, for an estimated $22,390,804
- ASSENAGON ASSET MANAGEMENT S.A. added 1,611,698 shares (+75.0%) to their portfolio in Q4 2025, for an estimated $20,307,394
- ROYAL BANK OF CANADA removed 1,529,485 shares (-99.4%) from their portfolio in Q4 2025, for an estimated $19,271,511
- MORGAN STANLEY added 1,315,018 shares (+37.5%) to their portfolio in Q4 2025, for an estimated $16,569,226
- PFM HEALTH SCIENCES, LP added 1,109,662 shares (+311.9%) to their portfolio in Q4 2025, for an estimated $13,981,741
- D. E. SHAW & CO., INC. added 1,096,643 shares (+70.1%) to their portfolio in Q4 2025, for an estimated $13,817,701
- PENN CAPITAL MANAGEMENT COMPANY, LLC added 1,001,951 shares (+inf%) to their portfolio in Q4 2025, for an estimated $12,624,582
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AMNEAL PHARMACEUTICALS Government Contracts
We have seen $311,472 of award payments to $AMRX over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PHARMACEUTICAL - XYREM (SODIUM OXYBATE): $311,472
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
AMNEAL PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $AMRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 10/31/2025
To track analyst ratings and price targets for AMNEAL PHARMACEUTICALS, check out Quiver Quantitative's $AMRX forecast page.
AMNEAL PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $AMRX recently. We have seen 3 analysts offer price targets for $AMRX in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $15.0 on 12/09/2025
- David Amsellem from Piper Sandler set a target price of $13.0 on 10/31/2025
- Chris Schott from JP Morgan set a target price of $14.0 on 09/16/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
